



# Figure S1

A



B



**Figure S1.** Synergistic effect of trametinib and panobinostat combination on cell viability in (A) *BRAF*<sup>V600E</sup> mutant (COLO 201), *BRAF*/*KRAS* WT (DIFI) and *KRAS* mutant (HCT 116) CRC cell lines and (B) patient derived colorectal tumour organoids (PDO's) that were treated in a 5 x 5 dose matrix of trametinib and panobinostat for 72 hours and cell viability assessed using the MTS and MTT assay, respectively. Data shown are from a single representative experiment performed in quadruplicate. Synergy, additivity or antagonism was assessed by using the bliss independent and HSA excess percentage methods. Synergy is denoted by darker red colours whereas blue is indicative of antagonism.